Almirall SA (ALM.MC)
23 Oct 2020
Mon, Jul 27 2020
BARCELONA, July 27 Spanish pharmaceutical firm Almirall lowered its 2020 outlook on Monday, forecasting a decrease in net sales and core earnings after the coronavirus pandemic hit its dermatology business, bringing net profit down 31.5% in the first semester.
* SAID ON THURSDAY IT DIVESTED ANSIOLIN (DIAZEPAM) TO NEURAXPHARM IN ITALY
* ALMIRALL ANNOUNCES FDA APPROVAL OF UPDATED LABEL FOR SEYSARA® (SARECYCLINE) TABLETS
* CFO says will be cautious looking for market opportunities (Adds CFO interview quotes, share details)
BARCELONA, May 11 Spain's Almirall does not expect to swing to a loss in the second quarter but its profit may decrease as it deals with the coronavirus pandemic's impact, its Chief Financial Officer Mike McClellan told Reuters on Monday .
BARCELONA, May 11 Spain's Almirall reported on Monday its first quarter net profit rose 63% and kept its 2020 outlook though it added the novel coronavirus pandemic evolution in the second quarter may prompt an outlook revision.
* Q1 REVENUE 247.3 MILLION EUROS VERSUS 232.2 MILLION EUROS YEAR AGO